Antibiotic Selection for Skin Cellulitis
For uncomplicated, non-purulent cellulitis, order oral cephalexin 500 mg four times daily or penicillin-based antibiotics for 5-7 days; for severe cellulitis or when MRSA is suspected, order IV vancomycin 30 mg/kg/day in 2 divided doses or oral trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily. 1
Oral Antibiotics for Non-Purulent Cellulitis
For mild to moderate cellulitis without purulence (no abscess or drainage), the primary pathogens are methicillin-sensitive Staphylococcus aureus (MSSA) and beta-hemolytic streptococci 2. First-line oral options include:
- Cephalexin 500 mg four times daily - most convenient with good suspension availability for pediatrics (25-50 mg/kg/day in 4 divided doses) 1
- Dicloxacillin 500 mg four times daily - oral agent of choice for MSSA in adults 1
- Amoxicillin or penicillin - appropriate for streptococcal coverage 2
Treatment duration: 5 days is sufficient for uncomplicated cases 3, though guidelines suggest 7-14 days based on clinical response 4. The shorter duration prevents unnecessary antibiotic exposure.
Critical Pitfall: Avoid Routine MRSA Coverage
Do not routinely cover MRSA in non-purulent cellulitis, even with rising community-acquired MRSA rates 2. MRSA coverage is only warranted when specific risk factors are present (see below).
When to Cover MRSA
Add MRSA-active antibiotics when patients have:
- Purulent drainage or abscess
- Failed initial beta-lactam therapy
- Systemic inflammatory response (fever >38°C, tachycardia >90, WBC >12,000)
- Recent MRSA infection or colonization
- Injection drug use
- Recent hospitalization or nursing home residence 1, 4
Oral MRSA-active options:
- Trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily (8-12 mg/kg based on TMP component in children) - highest treatment success rates at 91% vs 74% for cephalexin in MRSA-prevalent areas 5
- Doxycycline 100 mg twice daily (not for age <8 years) 1
- Clindamycin 300-450 mg four times daily (20 mg/kg/day in 3 divided doses for children) - but resistance is increasingly common 4
- Linezolid 600 mg twice daily - expensive but highly effective 4
For dual coverage of streptococci and MRSA: Combine TMP-SMX or doxycycline with a beta-lactam (cephalexin or amoxicillin) 4.
Intravenous Antibiotics for Severe Cellulitis
Use IV antibiotics when patients have:
- Systemic toxicity with hypotension
- Rapidly spreading infection
- Immunocompromised state
- Failed oral therapy 1
For MSSA (non-purulent, severe):
- Nafcillin or oxacillin 1-2 g every 4 hours IV - parenteral drug of choice (100-150 mg/kg/day in children) 1
- Cefazolin 1 g every 8 hours IV - more convenient, less bone marrow suppression, appropriate for penicillin allergy except immediate hypersensitivity (50 mg/kg/day in children) 1
For MRSA (purulent or severe with risk factors):
- Vancomycin 30 mg/kg/day in 2 divided doses IV - parenteral drug of choice for MRSA (40 mg/kg/day in 4 divided doses for children) 1, 4
- Daptomycin 4 mg/kg every 24 hours IV - bactericidal alternative 1, 4
- Linezolid 600 mg every 12 hours IV - can transition seamlessly to oral 4
- Ceftaroline 600 mg twice daily IV - newer beta-lactam with MRSA activity 1, 4
IV to Oral Transition
Switch to oral antibiotics when:
- Cellulitis stops advancing (typically 1-2 days) 6
- Patient is afebrile
- Able to tolerate oral intake
- Clinical stability achieved 4
Evidence shows oral antibiotics are non-inferior to IV for uncomplicated cellulitis, with mean time to cessation of advancement of 1.29 days for oral vs 1.78 days for IV 6.
Key Clinical Considerations
Before diagnosing cellulitis, rule out mimickers:
- Venous stasis dermatitis (most common mimic)
- Deep venous thrombosis
- Contact dermatitis
- Lymphedema
- Bilateral cellulitis is rare - if bilateral, strongly consider alternative diagnosis 3, 2
Laboratory testing is not routinely needed for uncomplicated cellulitis. Blood cultures have poor sensitivity. White blood cell count can indicate severity but is not required for diagnosis 3.
For abscesses: Incision and drainage is the primary treatment, followed by antibiotics (clindamycin or TMP-SMX) to reduce treatment failure 3.
The evidence strongly supports narrow-spectrum antibiotics for typical cellulitis, reserving broad-spectrum and MRSA-active agents for specific clinical scenarios. This approach balances effective treatment with antimicrobial stewardship.